Neuphoria Therapeutics
At Neuphoria Therapeutics, we are dedicated to pioneering breakthrough therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is developing BNC-210, a Ph3-First- and-Best-in-Class α-7 Nicotinic Receptor for the Treatment of SAD and PTSD. We also recently announced a $15M milestone payment from Merck for MK-1167, a PAM (Positive Allosteric Modulator) for treating Alzheimer's disease currently in P2 highlighting the strength and credibility of our scientific approach.
Address
BurlingtonMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}